Co-lead investors RA Capital and RTW Investments, LP invest alongside existing investor BVF Partners and other new investors in Series B financing Use of proceeds to support further clinical development of GH001 (5-MeO-DMT) in Treatment-Resistant Depression (TRD) and to advance GH001 into further clinical development in additional psychiatric and neurological disorders DUBLIN, April 12, 2021 /


Previous articleRed Light Holland Enters into Letter of Intent to Acquire Controlling Stake in Happy Caps Mushroom Farm based in Halifax, Nova Scotia
Next articlePsyched Wellness Receives DTC Eligibility